BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) released its earnings results on Friday. The company reported ($0.12) EPS for the quarter, FiscalAI reports. BioNexus Gene Lab had a negative net margin of 54.70% and a negative return on equity of 37.43%. The business had revenue of $0.08 million for the quarter.
BioNexus Gene Lab Trading Down 4.3%
NASDAQ:BGLC opened at $1.57 on Friday. The company has a quick ratio of 5.69, a current ratio of 6.53 and a debt-to-equity ratio of 0.01. BioNexus Gene Lab has a 1-year low of $1.07 and a 1-year high of $6.10. The firm has a market capitalization of $3.80 million, a price-to-earnings ratio of -1.25 and a beta of 4.16. The stock has a fifty day simple moving average of $1.85 and a 200 day simple moving average of $2.14.
Institutional Trading of BioNexus Gene Lab
A hedge fund recently raised its position in BioNexus Gene Lab stock. DRW Securities LLC grew its position in BioNexus Gene Lab Corp. (NASDAQ:BGLC – Free Report) by 226.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,830 shares of the company’s stock after buying an additional 33,179 shares during the quarter. DRW Securities LLC owned approximately 2.02% of BioNexus Gene Lab worth $189,000 at the end of the most recent quarter. 18.85% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on BGLC
About BioNexus Gene Lab
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.
Featured Stories
- Five stocks we like better than BioNexus Gene Lab
- AMG’s Alternatives Boom Powers Record Growth
- Microsoft’s Maia 300 Chip Targets NVIDIA’s AI Dominance
- 3 Unexpected ETFs Crushing the Market This Summer
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.
